DNMT1 and ovarian carcinoma: TGFβ has been shown to elevate CD133 expression via demethylation of the CD133 P1 promoter by inhibiting the expression of DNMT1 and DNMT3β [37] and Promoter methylation decreased CD133 expression in ovarian cancer and glioblastoma [33, 38].